ICYMI, this week we had stories about rising derm stars from the World Congress of Dermatology, secukinumab for pediatric patients with plaque psoriasis, remibrutinib for rapid symptom control of urticaria, and more.
More understanding of the physical, psychological, and economic burdens of hyperhidrosis is needed.
This Psoriasis Awareness Month, test your knowledge of the condition. Click here to answer this week's poll.
During the 25th World Congress of Dermatology, 40 rising stars and personalities were spotlighted for their contributions to the field.
Studies showed the various treatments improved symptoms, but more trials need to be done.
Clinicians can focus on patient care and leave human resources and bookkeeping to office staff.
In this week’s Pointers With Portela, the 208SkinDoc answers frequently asked questions about sunscreen use.
From bug bites to poison ivy, the skin can be exposed to a large spectrum of trouble while patients spend extended time outside.
Clinically asymptomatic patients receiving alternatives to conventional follow-up had a higher 3-year overall survival rate.
The guidance draft, once finalized, will enable the US FDA to have more oversight in the realm of cosmetic safety.
Researchers conducted systematic mapping of relevant DHI literature to determine the impact of these interventions on dermatologic care outcomes.
In subgroups based on age and bodyweight, treatment with secukinumab did not create new safety signals.
A grant from the National Institutes of Health will support continued research to develop products for soft tissue regeneration.
This week’s collection of the latest dermatologic studies covers an evaluation of the human stratum corneum with confocal Raman micro-spectroscopy, anti-mBP180 antibodies from mice, an updated review of alopecia areata comorbidities, and an ecchymotic patch related to chronic lymphocytic leukemia.
With hormonal fluctuations, constantly changing schedules, and various afterschool activities, addressing the specific needs of teenage skin becomes essential to promote a lifetime of proper skin care practices.
Dermatology Times is counting down to the annual fall SDPA conference in Nashville, Tennessee, with our top 10 headlines and highlights from this year's summer conference.
Research showed that many patients with skin cancer who had been treated using immunotherapy, such as immune checkpoint inhibition, experienced chronic side effects.
Patients given LNK01001 showed significant improvement in EASI scores over placebo.
Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.
The treatments also led to a decrease in the density of immunohistochemistry of sweat glands.
At 3 months post-treatment, skin texture and laxity showed significant improvement.
The highly selective oral BTK inhibitor is emerging in the treatment landscape as a potential therapeutic option for urticaria uncontrolled by H1-antihistamines.
In a survey, 99% of aesthetic practitioners and professionals said the product made lips look full and healthy.
Genetic variants associated with hidradenitis suppurativa (HS) were identified, although a causal effect is not proven.
Back-to-school season is an opportunity for dermatology clinicians to empower pediatric, adolescent, and young adult patients with treatment solutions for diagnoses including acne, atopic dermatitis, and skin cancer.
Investigators wanted to find a testing option if other parameters are negative or conflicting and LE is suspected.